Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...

To turbocharge disease-specific immune responses in patients, CAR-T cells are produced by removing a person's immune T cells ...

The global challenge posed by HIV-1 infection continues to drive research into its underlying mechanisms and the host immune response. Central to this pursuit is the role of T cells, particularly CD4 ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs—commonly referred to as antiretroviral therapy—the virus usually rushes ...

The experimental HIV vaccine regimen exhibited an acceptable safety profile and elicited robust immune responses in 99% of trial participants from sub-Saharan Africa. Its ability to induce broad ...

Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given. HARARE, ZIMBABWE, ROME, ITALY, NEW YORK, NY, AND CAMBRIDGE, MA / ACCESS ...

Scanning electron micrograph showing HIV (yellow) attacking a human T cell (blue). In a new study, Johns Hopkins Medicine-led researchers report on a person living with HIV who had a dramatic drop in ...

A new study has overcome a long-standing challenge: how to isolate and study elusive HIV-infected cells called authentic reservoir clones (ARCs) that evade the immune system, making the disease ...

Advancements in HIV/AIDS research, drug development, and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check ...